SCHEMBL4548634

SCHEMBL4548634

CC1=CC=NCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824741 0.71
SCHEMBL13063118 0.67
SCHEMBL13114692 0.67
SCHEMBL17413910 0.67
SCHEMBL7494508 0.67
SCHEMBL18525736 0.65
SCHEMBL2531786 0.64
SCHEMBL13456399 0.62
SCHEMBL8015824 0.60
SCHEMBL18942790 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11778902-B2 Organic electroluminescent devices KUNSHAN GO-VISIONOX OPTO-ELECTRONICS CO., LTD. (CN) 2023-10-03 US disclosed
EP-3704089-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-19 EP disclosed
EP-3452456-B1 BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-05 EP disclosed
WO-2022090514-A1 CIRCULARLY POLARIZED OLED EMITTING LAYER COMPOSITION UNIVERSITE DE RENNES 1 (FR) 2022-05-05 WO disclosed
EP-3798214-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2021-03-31 EP disclosed
WO-2021055612-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL-BioTech Investments, Inc. (US) 2021-03-25 WO disclosed
EP-3189042-B1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2021-03-17 EP disclosed
EP-3336084-B1 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2021-03-17 EP disclosed
EP-3526198-B1 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS BRISTOL MYERS SQUIBB CO (US) 2020-08-12 EP disclosed
WO-2019079607-A1 METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS Epizyme, Inc. (US) 2019-04-25 WO disclosed
WO-2009011410-A1 AMPA RECEPTOR ANTAGONISTS AND ALDOSE REDUCTASE INHIBITORS FOR NEUROPATHIC PAIN EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-01-22 WO disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20070238871-A1 Glycolipids And Analogues Thereof As Antigens For NKT Cells THE ROCKEFELLER UNIVERSITY (US) 2007-10-11 US disclosed
US-20070238871-A1 Glycolipids And Analogues Thereof As Antigens For NKT Cells THE ROCKEFELLER UNIVERSITY (US) 2007-10-11 US disclosed
WO-2007107383-A1 INDOLE DERIVATIVES AS INHIBITORS OF THE SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-09-27 WO disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1699795-B1 SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES SANOFI AVENTIS (FR) 2007-04-25 EP disclosed
US-20070037774-A1 Cytarabine monophosphate (araCMP) cyclic diesters of 1,3 propane-1-(4-pyridyl) diols that (5'-O-cis-[4-(4-pyridyl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta -D-arabinofuranoside); liver cancer; liver disorders; liver viral infections; activates cytochrome P450; side effect reduction; half-life CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2007-02-15 US disclosed
WO-2007006546-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
WO-2006107859-A2 DIHYDROPYRIDINE COMPOUNDS FOR NEURODEGENERATIVE DISEASES AND DEMENTIA EISAI CO., LTD. (JP) 2006-10-12 WO disclosed